Navigation Links
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Date:3/13/2009

in Peripheral T-Cell Lymphomas Overexpressing Activated Syk" suggested that Syk may play a critical role in some PTCLs and represents a feasible therapeutic target for further clinical study.

Phase 2 Design

The Phase 2 trial will be conducted in two stages at several centers in North America with each patient receiving 200mg of R788 twice a day for a minimum of 8 weeks, or until disease progression or withdrawal from the trial. During stage one, 19 men and women with PTCL who have previously failed to respond to standard of care treatment for their disease are expected to be evaluated. Stage two is expected to include the enrollment of approximately 36 patients. Efficacy will be assessed by CT/PET scans at baseline and CT scans of the disease-involved areas at 8 weeks. Safety will be assessed by periodic physical exams, blood tests and clinical laboratory work, among others. Results of the clinical trial are expected in the second half of 2010.

In June 2008, Rigel first reported results of a Phase 2 clinical trial of R788 in the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphomas. R788 was well-tolerated in this patient population and showed therapeutic benefit in patients suffering from certain subcategories of the disease, especially small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and diffuse large B-cell lymphoma. More details about the outcome of that clinical trial and the role that Syk inhibition may play in the treatment of lymphoma patients can be found at Rigel's website, http://www.rigel.com/rigel/lymphoma.

About Rigel

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intrace
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
3. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
4. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
8. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
9. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
10. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... BEDFORD, Mass. , April 16, 2015 /PRNewswire/ ... an important cervical cancer screening study i ... , a peer-reviewed journal of the American Cancer ... Quest Diagnostics and the University of Pittsburgh Medical Center, supports ... screening, which recommend that women 30-65 years of ...
(Date:4/16/2015)... 2015 Mallinckrodt plc (NYSE: MNK ... that it has completed its acquisition of Ikaria, ... billion. The Ikaria acquisition extends Mallinckrodt,s footprint in ... neonatal critical care with INOMAX ® (inhaled ... highly vulnerable patient population. It also accelerates Mallinckrodt,s ...
(Date:4/16/2015)... 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) announced ... with a newly formed specialty healthcare company focused ... addressing urological disorders. The merged company, which is ... commenced operations and incorporates the pipeline assets of ... strategy is to build a late-stage and commercial ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
(Date:4/18/2015)... 2015 Insuranceautoquote.info has released a new ... insurance quotes . , Clients can review important ... The online environment provides important advantages for clients who ... Drivers who do not have coverage for their vehicles ... season, day or hour. Many agencies offer important discounts ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Association Annual Conference to be held May 1-2, ... , The SCAPTA Annual Conference offers educational ... services. , Representatives from Aureus Medical’s ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant ... Week Celebration on April 20 with a day full ... body and soul. , The community, which is located ... adults of all incomes, including those on Medicaid, who ... Living Week is observed every April and highlights the ...
(Date:4/17/2015)... 2015 Riviera Magazine has ... of the Gallery of Cosmetic Surgery in Newport ... experts. The publication focused on his expertise in ... fat grafting, eyelid surgery, laser resurfacing and rhinoplasty. , ... has resulted in thousands of satisfied patients across ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... a local newspaper to pay compensation and apologise to a ... for unethical reporting.// ,Beijing Chaoyang District Court ordered ... yuan (2,500 US dollars) and issue an apology on its ... report carried three photos of the woman and the story ...
... Gemzar for the treatment of recurrent ovarian cancer ignoring the ... that Gemzar in combination with carboplatin (chemotherapy) is very effective ... also known by its generic name gemcitabine and was approved ... According to the statistics of the American Cancer Society about ...
... "Tobacco Kills/Smoking Kills" -- such health warnings would be ... sellers would attract stringent penalty including imprisonment. // ... packages include "Skull and Bones Sign" or a pictorial ... message., ,The Health and Family Welfare Ministry headed ...
... than half of human cancers involve mutations in the ... the normal p53 protein in defending// against cancer. Similarly, ... protein occur in its DNA-binding core domain, pointing to ... to its anti-cancer activity. ,Clearly, a detailed ...
... Canterbury University researcher Dr Victoria Metcalf is out to ... fish. Metcalf will use the genetic filter technology// to ... aid in the understanding of the existing connection between ... Metcalf, Antarctic fish metabolize fat for fuel, unlike humans ...
... Health (MOH) says that Singapore will soon conduct a ... Readiness.// , More than 1,000 personnel from ... of Education, the Civil Aviation Authority of Singapore, Immigration ... in the exercise code-named SPARROWHAWK II. , ...
Cached Medicine News:Health News:DNA-bound p53 Tumor Suppressor Protein Structure Determined 2
... Used for catheter positioning ... procedures. Increased inner diameter ... allows utilization of an ... while maintaining tip flexibility. ...
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: